Mimedx Group Inc (MDXG) 9.46 $MDXG
MiMedx Announces Publication Of Latest Scientific Study Demonstrating The Ability Of Its Allografts To Regulate Diabetic Stem Cells
PR Newswire - Wed Aug 26, 8:40AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its latest peer-reviewed scientific study, "Type I and II diabetic adipose derived stem cells respond in vitro to dehydrated human amnion/chorion membrane allograft treatment by increasing proliferation, migration, and altering cytokine secretion" was electronically published in Advances in Wound Care.
MDXG: 9.46 (+0.35)
MiMedx Patent Infringement Lawsuits Receive Favorable Rulings From Patent Trial And Review Board
PR Newswire - Fri Aug 21, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today the Patent Trial and Appeal Board ("PTAB"
has ruled in favor of the Company's primary EpiFix® and AmnioFix® patents.
MDXG: 9.46 (+0.35)
'Mad Money' Lightning Round: Buy, Buy, Buy MGM Resorts
at The Street - Tue Aug 11, 5:00AM CDT
Cramer likes Enterprise Products Partners, says Dave and Busters is in a tough business and thinks Helen of Troy should be higher.
RDUS: 61.70 (+3.93), HELE: 84.83 (+1.30), PLAY: 33.46 (+1.04), MGM: 19.61 (+0.40), MDXG: 9.46 (+0.35), EPD: 27.26 (+1.04)
Jim Cramer's 'Mad Money' Recap: 10 Things That Created Today's Market Rally
at The Street - Mon Aug 10, 7:23PM CDT
Warren Buffett was one reason for the rally, Cramer says. Here are nine more.
SNA: 155.69 (+4.21), L: 35.79 (+0.43), XOM: 72.50 (+3.79), CB: 120.49 (+1.32), PCP: 228.88 (+0.38), ETR: 64.29 (+0.69), INO: 6.80 (+0.21), DO: 21.72 (+0.22), AMAT: 15.24 (+0.40), GOOGL: 659.74 (+47.27), HSIC: 137.27 (+5.04), AAPL: 109.69 (+5.95), MDXG: 9.46 (+0.35), SE: 27.14 (+1.01), MGM: 19.61 (+0.40), WWAV: 44.86 (+2.76), HELE: 84.83 (+1.30), NFLX: 110.13 (+8.61), RDUS: 61.70 (+3.93), AA: 8.26 (+0.15), LEN: 49.70 (+1.52), AZN: 31.13 (+0.85), PLAY: 33.46 (+1.04), PG: 70.90 (+2.48), GIS: 55.89 (+1.08), EPD: 27.26 (+1.04)
MiMedx Updates Second Quarter Information
PR Newswire - Thu Aug 06, 11:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that MiMedx management has responded to numerous questions relative to its second quarter report. From the Company's standpoint, these questions have already been addressed after first and second quarter conference calls. However, there has been some misinterpretation and misinformation since this quarter's press release and conference call which the Company seeks to clarify.
MDXG: 9.46 (+0.35)
Medical Appliances and Equipment Stocks Technical Report -- Accuray, MiMedx Group, InspireMD, Wright Medical Group, and Second Sight Medical Products
PR Newswire - Tue Aug 04, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Accuray Inc. (NASDAQ: ARAY), MiMedx Group Inc. (NASDAQ: MDXG), InspireMD Inc. (AMEX: NSPR), Wright Medical Group Inc. (NASDAQ: WMGI), and Second Sight Medical Products Inc. (NASDAQ: EYES). Free research report on Accuray can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=ARAY On Monday, August 03, 2015, the NASDAQ Composite ended at 5,115.38, down 0.25%, the Dow Jones Industrial Average lost 0.52%, to finish the day at 17,598.20, and the S&P 500 closed at 2,098.04, down 0.28%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
EYES: 9.14 (+0.32), WMGI: 23.48 (+0.36), WMGIZ: 3.63 (unch), NSPR: 0.18 (-0.01), ARAY: 6.42 (-0.05), MDXG: 9.46 (+0.35)
MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference
PR Newswire - Mon Aug 03, 1:00PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at the 35th Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Wednesday, August 12, 2015, at 5:00 p.m. EDT, at the InterContinental Boston. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 9.46 (+0.35)
MiMedx Announces Record Results for Second Quarter of 2015
PR Newswire - Thu Jul 30, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for the second quarter of 2015.
MDXG: 9.46 (+0.35)
Wound Care - Traditonal, Advanced And Regenerative: Global Markets, Competitors And Opportunities: 2015-2020
M2 - Mon Jul 27, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6v8fh/wound_care) has announced the addition of the "Wound Care -Traditonal, Advanced And Regenerative-Global Markets, Competitors And Opportunities: 2015-2020 Analysis And Forecasts" report to their offering. Comprehensive information and evaluation of the global Wound Care products market, with detailed analysis of manufacturers, segmentation, product offerings, competitive shares, financial performance, technology developments and market drivers. Additionally, 20 key Wound Care product suppliers are fully analyzed and profiled. A must-read compendium of information and analysis that will provide executives with a significant knowledge of global market, product, technology and financial developments in this industry. Hard factual information in 202 pages, illustrated with 53 tables and 42 charts and figures. The only published report of its kind, with in-depth detail not found elsewhere in similar studies. Products Covered: - Bandages, Tapes, Gauze - Alginate Dressings - Foam Dressings - Antimicrobial Dressings - Hydrogels - Hydrocolloids - Bioengineered Skin - Skin Substitutes - Biologic Substances - Pulsed Radio Frequency Energy - Pulsed Electrmagnetic Fields - Wound Closure - Wound Management - Pressure Relief - Sutures, Staples, Adhesives, - Collagen Sealants Companies Mentioned - 3M Company - Advanced Medical Solutions Group plc - Alliqua BioMedical, Inc. - Avita Medical Ltd. - Centaur Guernsey L.P. Inc. - Coloplast A/S - Covidien plc - CytoTools AG - Cytomedix, Inc. - Derma Sciences, Inc. - Essex Bio-Technology Ltd. - Japan Tissue Engineering Co., Ltd. - Johnson & Johnson - Macrocure Ltd - MiMedx Group, Inc. - Novadaq Technologies Inc. - Osiris Therapeutics, Inc. - SANUWAVE Health, Inc. - Smith & Nephew Plc - Tissue Regenix Group plc For more information visit http://www.researchandmarkets.com/research/v6v8fh/wound_care
DSCI: 5.81 (-0.19), SNN: 34.39 (+0.15), JNJ: 95.11 (+4.38), MMM: 142.72 (+5.08), OSIR: 18.01 (+0.66), MDXG: 9.46 (+0.35), NVDQ: 11.06 (unch)
Scientific Study Demonstrates That MiMedx Allografts Stimulate Cellular Proliferation And Migration In A Variety Of Adult Stem Cells
PR Newswire - Wed Jul 15, 3:00PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its latest peer-reviewed scientific study, "Dehydrated Human Amnion/Chorion Membrane Regulates Stem Cell Activity In Vitro," was electronically published in the Journal of Biomedical Materials Research: Part B - Applied Biomaterials.
MDXG: 9.46 (+0.35)
MiMedx (MDXG) Worth a Look: Stock Adds 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 8:46AM CDT
MiMedx Group, Inc. (MDXG) was a big mover last session, as the company saw its shares rise over 5% on the day.
AMAG: 63.26 (+4.30), MDXG: 9.46 (+0.35)
MiMedx Announces Release Date for 2015 Second Quarter Results
PR Newswire - Wed Jul 08, 1:25PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its results for the second quarter ended June 30, 2015, will be released before the opening of the market on Thursday, July 30, 2015. MiMedx will host a live broadcast of its second quarter conference call on Thursday, July 30, 2015 at 10:30 a.m. EDT. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website at www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MDXG: 9.46 (+0.35)
EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx
PR Newswire - Mon Jun 29, 12:18PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced that its Chairman and CEO, Parker H. "Pete" Petit, has been awarded the Lifetime Achievement Award in the EY Entrepreneur Of The Year® 2015 Southeast Program.
MDXG: 9.46 (+0.35)
MiMedx Group (MDXG) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 24, 7:05AM CDT
MiMedx Group (MDXG) Shares March Higher, Can It Continue?
MDXG: 9.46 (+0.35)
The Priceline Group Set to Join the S&P 100; Baxalta to Join the 500; Other Changes to S&P MidCap 400 & S&P SmallCap 600
PR Newswire - Fri Jun 19, 5:13PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 100, S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
RKT: 61.97 (+1.77), ITRI: 29.50 (-0.45), QEP: 11.56 (+0.25), MWV: 48.30 (+1.11), ACI: 5.09 (+0.94), BAX: 37.67 (+0.70), HQY: 28.69 (+0.45), SKX: 137.29 (+5.33), MHFI: 96.27 (+3.08), ZEP: 20.04 (+0.02), MDXG: 9.46 (+0.35), PCLN: 1,223.46 (+44.65)
MiMedx up 5% premarket after CNBC interview with CEO
Seeking Alpha - at Seeking Alpha - Wed Jun 17, 8:02AM CDT
MDXG: 9.46 (+0.35)
A New Spin On The Price/Sales Ratio: The PSG Ratio
Thomas Pound - at Seeking Alpha - Fri Jun 12, 2:04AM CDT
VEC: 25.19 (+0.96), ACHC: 70.41 (+0.26), HK: 0.92 (+0.02), CTRX: 61.47 (+0.04), NOG: 4.80 (+0.23), CTIC: 1.51 (-0.09), RUSHA: 24.09 (+0.24), PARR: 18.32 (+0.43), REGI: 7.30 (-0.37), RCAP: 1.96 (-0.11), ECYT: 5.05 (+0.22), ZLTQ: 32.85 (+0.34), INT: 37.78 (+0.69), P: 17.64 (+0.55), TWO: 9.52 (+0.12), NLNK: 46.45 (+1.30), SHLO: 10.34 (+0.21), REI: 8.37 (+0.36), SYRG: 9.89 (+0.34), PEIX: 6.22 (-0.09), AAPL: 109.69 (+5.95), MDXG: 9.46 (+0.35), FSIC: 9.79 (+0.05), TA: 11.84 (+0.39), QUAD: 14.10 (+0.19), SPTN: 30.19 (+1.16), CJES: 3.50 (+0.30), ZEUS: 12.50 (+0.27), PBF: 28.72 (+0.62), CZNC: 19.74 (+0.24), SSE: 2.21 (+0.19), VMEM: 2.18 (+0.28), PSG: 13.55 (+0.21), OREX: 2.70 (+0.03), LC: 12.17 (+0.17), PACB: 4.58 (+0.12), UDF: 17.25 (+0.24), AE: 43.04 (-0.41), BIOS: 2.27 (-0.03), GPT: 22.55 (+0.40), BRG: 11.22 (+0.49), NSAM: 16.73 (+0.62)
Looking for a Growth Stock? Why It is Time to Focus on MiMedx (MDXG) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 02, 7:51AM CDT
MiMedx has actually seen estimates rise over the past month for the current fiscal year by about 20% and currently has a Zacks Rank #2 (Buy)
MDXG: 9.46 (+0.35)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri May 29, 7:14PM CDT
Cramer is advising caution as he awaits more company earnings and the all-important non-farm payroll report next week.
GD: 144.05 (+5.21), LMT: 202.12 (+3.14), SHAK: 47.68 (+2.79), MDT: 72.24 (+2.36), APLE: 16.96 (+0.58), UTX: 91.56 (+2.76), RTN: 103.62 (+2.97), GLUU: 4.20 (+0.01), CIEN: 22.33 (+1.93), PVH: 111.44 (+2.22), SJM: 109.15 (+2.30), HUM: 180.73 (+5.27), LUV: 37.39 (+0.87), BSX: 16.37 (+0.59), JACK: 79.93 (+1.21), DPZ: 106.30 (+1.28), DG: 76.71 (+2.98), LYG: 4.84 (+0.10), MDXG: 9.46 (+0.35), ROIC: 16.06 (+0.31), FEYE: 38.15 (+1.60), RRGB: 79.06 (+0.11), ADRO: 19.34 (+1.42), GME: 45.36 (+1.47), HABT: 23.95 (+0.46), ACHN: 7.34 (+0.24), MCD: 95.15 (+3.94), PAY: 30.44 (+0.99), BF.B: 98.27 (+0.05), WEN: 9.00 (+0.01)
MiMedx To Present At The Jefferies 2015 Global Healthcare Conference
PR Newswire - Wed May 27, 8:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at the Jefferies 2015 Global Healthcare Conference in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Wednesday, June 3rd at 8:30 a.m. EDT, at the Grand Hyatt New York. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 9.46 (+0.35)
MiMedx Announces Publication Of Latest Scientific Study Demonstrating The Ability Of Its Allografts To Regulate Diabetic Stem Cells
PR Newswire - Wed Aug 26, 8:40AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its latest peer-reviewed scientific study, "Type I and II diabetic adipose derived stem cells respond in vitro to dehydrated human amnion/chorion membrane allograft treatment by increasing proliferation, migration, and altering cytokine secretion" was electronically published in Advances in Wound Care.
MDXG: 9.46 (+0.35)
MiMedx Patent Infringement Lawsuits Receive Favorable Rulings From Patent Trial And Review Board
PR Newswire - Fri Aug 21, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today the Patent Trial and Appeal Board ("PTAB"
has ruled in favor of the Company's primary EpiFix® and AmnioFix® patents. MDXG: 9.46 (+0.35)
'Mad Money' Lightning Round: Buy, Buy, Buy MGM Resorts
at The Street - Tue Aug 11, 5:00AM CDT
Cramer likes Enterprise Products Partners, says Dave and Busters is in a tough business and thinks Helen of Troy should be higher.
RDUS: 61.70 (+3.93), HELE: 84.83 (+1.30), PLAY: 33.46 (+1.04), MGM: 19.61 (+0.40), MDXG: 9.46 (+0.35), EPD: 27.26 (+1.04)
Jim Cramer's 'Mad Money' Recap: 10 Things That Created Today's Market Rally
at The Street - Mon Aug 10, 7:23PM CDT
Warren Buffett was one reason for the rally, Cramer says. Here are nine more.
SNA: 155.69 (+4.21), L: 35.79 (+0.43), XOM: 72.50 (+3.79), CB: 120.49 (+1.32), PCP: 228.88 (+0.38), ETR: 64.29 (+0.69), INO: 6.80 (+0.21), DO: 21.72 (+0.22), AMAT: 15.24 (+0.40), GOOGL: 659.74 (+47.27), HSIC: 137.27 (+5.04), AAPL: 109.69 (+5.95), MDXG: 9.46 (+0.35), SE: 27.14 (+1.01), MGM: 19.61 (+0.40), WWAV: 44.86 (+2.76), HELE: 84.83 (+1.30), NFLX: 110.13 (+8.61), RDUS: 61.70 (+3.93), AA: 8.26 (+0.15), LEN: 49.70 (+1.52), AZN: 31.13 (+0.85), PLAY: 33.46 (+1.04), PG: 70.90 (+2.48), GIS: 55.89 (+1.08), EPD: 27.26 (+1.04)
MiMedx Updates Second Quarter Information
PR Newswire - Thu Aug 06, 11:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that MiMedx management has responded to numerous questions relative to its second quarter report. From the Company's standpoint, these questions have already been addressed after first and second quarter conference calls. However, there has been some misinterpretation and misinformation since this quarter's press release and conference call which the Company seeks to clarify.
MDXG: 9.46 (+0.35)
Medical Appliances and Equipment Stocks Technical Report -- Accuray, MiMedx Group, InspireMD, Wright Medical Group, and Second Sight Medical Products
PR Newswire - Tue Aug 04, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Accuray Inc. (NASDAQ: ARAY), MiMedx Group Inc. (NASDAQ: MDXG), InspireMD Inc. (AMEX: NSPR), Wright Medical Group Inc. (NASDAQ: WMGI), and Second Sight Medical Products Inc. (NASDAQ: EYES). Free research report on Accuray can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=ARAY On Monday, August 03, 2015, the NASDAQ Composite ended at 5,115.38, down 0.25%, the Dow Jones Industrial Average lost 0.52%, to finish the day at 17,598.20, and the S&P 500 closed at 2,098.04, down 0.28%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
EYES: 9.14 (+0.32), WMGI: 23.48 (+0.36), WMGIZ: 3.63 (unch), NSPR: 0.18 (-0.01), ARAY: 6.42 (-0.05), MDXG: 9.46 (+0.35)
MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference
PR Newswire - Mon Aug 03, 1:00PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at the 35th Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Wednesday, August 12, 2015, at 5:00 p.m. EDT, at the InterContinental Boston. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 9.46 (+0.35)
MiMedx Announces Record Results for Second Quarter of 2015
PR Newswire - Thu Jul 30, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for the second quarter of 2015.
MDXG: 9.46 (+0.35)
Wound Care - Traditonal, Advanced And Regenerative: Global Markets, Competitors And Opportunities: 2015-2020
M2 - Mon Jul 27, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6v8fh/wound_care) has announced the addition of the "Wound Care -Traditonal, Advanced And Regenerative-Global Markets, Competitors And Opportunities: 2015-2020 Analysis And Forecasts" report to their offering. Comprehensive information and evaluation of the global Wound Care products market, with detailed analysis of manufacturers, segmentation, product offerings, competitive shares, financial performance, technology developments and market drivers. Additionally, 20 key Wound Care product suppliers are fully analyzed and profiled. A must-read compendium of information and analysis that will provide executives with a significant knowledge of global market, product, technology and financial developments in this industry. Hard factual information in 202 pages, illustrated with 53 tables and 42 charts and figures. The only published report of its kind, with in-depth detail not found elsewhere in similar studies. Products Covered: - Bandages, Tapes, Gauze - Alginate Dressings - Foam Dressings - Antimicrobial Dressings - Hydrogels - Hydrocolloids - Bioengineered Skin - Skin Substitutes - Biologic Substances - Pulsed Radio Frequency Energy - Pulsed Electrmagnetic Fields - Wound Closure - Wound Management - Pressure Relief - Sutures, Staples, Adhesives, - Collagen Sealants Companies Mentioned - 3M Company - Advanced Medical Solutions Group plc - Alliqua BioMedical, Inc. - Avita Medical Ltd. - Centaur Guernsey L.P. Inc. - Coloplast A/S - Covidien plc - CytoTools AG - Cytomedix, Inc. - Derma Sciences, Inc. - Essex Bio-Technology Ltd. - Japan Tissue Engineering Co., Ltd. - Johnson & Johnson - Macrocure Ltd - MiMedx Group, Inc. - Novadaq Technologies Inc. - Osiris Therapeutics, Inc. - SANUWAVE Health, Inc. - Smith & Nephew Plc - Tissue Regenix Group plc For more information visit http://www.researchandmarkets.com/research/v6v8fh/wound_care
DSCI: 5.81 (-0.19), SNN: 34.39 (+0.15), JNJ: 95.11 (+4.38), MMM: 142.72 (+5.08), OSIR: 18.01 (+0.66), MDXG: 9.46 (+0.35), NVDQ: 11.06 (unch)
Scientific Study Demonstrates That MiMedx Allografts Stimulate Cellular Proliferation And Migration In A Variety Of Adult Stem Cells
PR Newswire - Wed Jul 15, 3:00PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its latest peer-reviewed scientific study, "Dehydrated Human Amnion/Chorion Membrane Regulates Stem Cell Activity In Vitro," was electronically published in the Journal of Biomedical Materials Research: Part B - Applied Biomaterials.
MDXG: 9.46 (+0.35)
MiMedx (MDXG) Worth a Look: Stock Adds 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 8:46AM CDT
MiMedx Group, Inc. (MDXG) was a big mover last session, as the company saw its shares rise over 5% on the day.
AMAG: 63.26 (+4.30), MDXG: 9.46 (+0.35)
MiMedx Announces Release Date for 2015 Second Quarter Results
PR Newswire - Wed Jul 08, 1:25PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its results for the second quarter ended June 30, 2015, will be released before the opening of the market on Thursday, July 30, 2015. MiMedx will host a live broadcast of its second quarter conference call on Thursday, July 30, 2015 at 10:30 a.m. EDT. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website at www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MDXG: 9.46 (+0.35)
EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx
PR Newswire - Mon Jun 29, 12:18PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced that its Chairman and CEO, Parker H. "Pete" Petit, has been awarded the Lifetime Achievement Award in the EY Entrepreneur Of The Year® 2015 Southeast Program.
MDXG: 9.46 (+0.35)
MiMedx Group (MDXG) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 24, 7:05AM CDT
MiMedx Group (MDXG) Shares March Higher, Can It Continue?
MDXG: 9.46 (+0.35)
The Priceline Group Set to Join the S&P 100; Baxalta to Join the 500; Other Changes to S&P MidCap 400 & S&P SmallCap 600
PR Newswire - Fri Jun 19, 5:13PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 100, S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
RKT: 61.97 (+1.77), ITRI: 29.50 (-0.45), QEP: 11.56 (+0.25), MWV: 48.30 (+1.11), ACI: 5.09 (+0.94), BAX: 37.67 (+0.70), HQY: 28.69 (+0.45), SKX: 137.29 (+5.33), MHFI: 96.27 (+3.08), ZEP: 20.04 (+0.02), MDXG: 9.46 (+0.35), PCLN: 1,223.46 (+44.65)
MiMedx up 5% premarket after CNBC interview with CEO
Seeking Alpha - at Seeking Alpha - Wed Jun 17, 8:02AM CDT
MDXG: 9.46 (+0.35)
A New Spin On The Price/Sales Ratio: The PSG Ratio
Thomas Pound - at Seeking Alpha - Fri Jun 12, 2:04AM CDT
VEC: 25.19 (+0.96), ACHC: 70.41 (+0.26), HK: 0.92 (+0.02), CTRX: 61.47 (+0.04), NOG: 4.80 (+0.23), CTIC: 1.51 (-0.09), RUSHA: 24.09 (+0.24), PARR: 18.32 (+0.43), REGI: 7.30 (-0.37), RCAP: 1.96 (-0.11), ECYT: 5.05 (+0.22), ZLTQ: 32.85 (+0.34), INT: 37.78 (+0.69), P: 17.64 (+0.55), TWO: 9.52 (+0.12), NLNK: 46.45 (+1.30), SHLO: 10.34 (+0.21), REI: 8.37 (+0.36), SYRG: 9.89 (+0.34), PEIX: 6.22 (-0.09), AAPL: 109.69 (+5.95), MDXG: 9.46 (+0.35), FSIC: 9.79 (+0.05), TA: 11.84 (+0.39), QUAD: 14.10 (+0.19), SPTN: 30.19 (+1.16), CJES: 3.50 (+0.30), ZEUS: 12.50 (+0.27), PBF: 28.72 (+0.62), CZNC: 19.74 (+0.24), SSE: 2.21 (+0.19), VMEM: 2.18 (+0.28), PSG: 13.55 (+0.21), OREX: 2.70 (+0.03), LC: 12.17 (+0.17), PACB: 4.58 (+0.12), UDF: 17.25 (+0.24), AE: 43.04 (-0.41), BIOS: 2.27 (-0.03), GPT: 22.55 (+0.40), BRG: 11.22 (+0.49), NSAM: 16.73 (+0.62)
Looking for a Growth Stock? Why It is Time to Focus on MiMedx (MDXG) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 02, 7:51AM CDT
MiMedx has actually seen estimates rise over the past month for the current fiscal year by about 20% and currently has a Zacks Rank #2 (Buy)
MDXG: 9.46 (+0.35)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri May 29, 7:14PM CDT
Cramer is advising caution as he awaits more company earnings and the all-important non-farm payroll report next week.
GD: 144.05 (+5.21), LMT: 202.12 (+3.14), SHAK: 47.68 (+2.79), MDT: 72.24 (+2.36), APLE: 16.96 (+0.58), UTX: 91.56 (+2.76), RTN: 103.62 (+2.97), GLUU: 4.20 (+0.01), CIEN: 22.33 (+1.93), PVH: 111.44 (+2.22), SJM: 109.15 (+2.30), HUM: 180.73 (+5.27), LUV: 37.39 (+0.87), BSX: 16.37 (+0.59), JACK: 79.93 (+1.21), DPZ: 106.30 (+1.28), DG: 76.71 (+2.98), LYG: 4.84 (+0.10), MDXG: 9.46 (+0.35), ROIC: 16.06 (+0.31), FEYE: 38.15 (+1.60), RRGB: 79.06 (+0.11), ADRO: 19.34 (+1.42), GME: 45.36 (+1.47), HABT: 23.95 (+0.46), ACHN: 7.34 (+0.24), MCD: 95.15 (+3.94), PAY: 30.44 (+0.99), BF.B: 98.27 (+0.05), WEN: 9.00 (+0.01)
MiMedx To Present At The Jefferies 2015 Global Healthcare Conference
PR Newswire - Wed May 27, 8:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at the Jefferies 2015 Global Healthcare Conference in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Wednesday, June 3rd at 8:30 a.m. EDT, at the Grand Hyatt New York. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 9.46 (+0.35)
